Leerink Partnrs Has Bullish Outlook for Vaxcyte Q3 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Equities research analysts at Leerink Partnrs lifted their Q3 2025 EPS estimates for shares of Vaxcyte in a report issued on Wednesday, May 7th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of ($1.22) for the quarter, up from their prior forecast of ($1.23). The consensus estimate for Vaxcyte's current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for Vaxcyte's Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.09) EPS, FY2026 earnings at ($5.54) EPS, FY2027 earnings at ($5.75) EPS and FY2028 earnings at ($4.83) EPS.

Other analysts also recently issued research reports about the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. The Goldman Sachs Group dropped their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Guggenheim restated a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Cantor Fitzgerald started coverage on Vaxcyte in a research note on Tuesday, April 22nd. They set an "overweight" rating on the stock. Finally, Bank of America lowered their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Trading Down 4.9%

NASDAQ PCVX traded down $1.54 during trading on Monday, reaching $30.05. The company's stock had a trading volume of 2,665,021 shares, compared to its average volume of 1,321,417. The firm has a market capitalization of $3.88 billion, a price-to-earnings ratio of -6.53 and a beta of 1.27. Vaxcyte has a 12 month low of $27.66 and a 12 month high of $121.06. The firm has a 50 day moving average price of $45.81 and a 200 day moving average price of $73.63.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period in the previous year, the company earned ($0.85) EPS.

Institutional Investors Weigh In On Vaxcyte

Several institutional investors have recently added to or reduced their stakes in the business. Whipplewood Advisors LLC bought a new position in shares of Vaxcyte in the fourth quarter worth $28,000. Smartleaf Asset Management LLC grew its position in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after acquiring an additional 260 shares in the last quarter. National Bank of Canada FI purchased a new position in shares of Vaxcyte in the 4th quarter worth about $41,000. Blue Trust Inc. increased its position in shares of Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after purchasing an additional 371 shares during the last quarter. Finally, Assetmark Inc. raised its holdings in shares of Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after buying an additional 775 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $83.85, for a total transaction of $670,800.00. Following the transaction, the chief financial officer now owns 109,491 shares of the company's stock, valued at $9,180,820.35. This represents a 6.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.10% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.